股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年11月30日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 中國生物製藥有限公司 呈交日期: 2025年12月1日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 不適用 | | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 01177 | 說明 | - | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | 法定/註冊股本 | | | 上月底結存 | | | 30,000,000,000 | HKD | | 0.025 HKD | | 750,000,000 | | 增加 / 減少 (-) | | | 0 | | | HKD | | 0 | | 本月底結存 | | 30,000,000,000 | | HKD | | 0.025 HKD | | 750,000,000 | 本月底法定/註冊股本總額： ...

经济观察网 11月26日，香港新界大埔区宏福苑突发火灾，引发全国上下关切。 正大制药总裁郑翔玲、中国生物制药首席执行长谢承润27日宣布，公司捐赠1000万港元的现金及药品， 用于受灾同胞的紧急安置及过渡期基本生活保障所需。 ...

Core Viewpoint - Shanghai Baoji Pharmaceutical Co., Ltd. is preparing for an IPO on the Hong Kong Stock Exchange, with funds primarily allocated for the development and commercialization of core products and expansion of production capacity [1][2]. Group 1: IPO Details - The company has submitted its hearing materials and is expected to list soon, with CITIC Securities and Cathay Securities acting as joint sponsors [1]. - The funds raised will support clinical trials and regulatory filings for core products KJ017, KJ103, and SJ02 in various regions [1]. Group 2: Product Development - The company focuses on four strategic areas: large-volume subcutaneous delivery, antibody-mediated autoimmune diseases, assisted reproduction, and recombinant biopharmaceuticals [2]. - It has developed 12 research products, including three core products, with SJ02 already approved by the National Medical Products Administration (NMPA) [2]. - KJ017 is in the NDA stage, while KJ103 is in Phase III clinical trials [2]. Group 3: Technology and Production - The company aims to optimize its proprietary synthetic biology technology platform to develop new drug candidates [1]. - Plans include enhancing and expanding production capacity, including the construction of a new production base in Shanghai and upgrading existing facilities [1].

每经AI快讯，中国生物制药(01177.HK)涨近3%，截至发稿，涨2.87%，报7.16港元，成交额1.74亿港 元。 ...

Core Viewpoint - China Biopharmaceutical (01177) shares rose over 4%, currently up 2.87% at HKD 7.16, with a trading volume of HKD 174 million, following the publication of positive Phase II clinical trial results for TQB2102 in the treatment of HER2-positive breast cancer [1] Group 1 - TQB2102 is a targeted antibody-drug conjugate (ADC) developed by China Biopharmaceutical's subsidiary, Zhengda Tianqing, targeting two non-overlapping epitopes ECD2 and ECD4 of HER2 [1] - The Phase II clinical study, led by Professor Shao Zhimin's team from Fudan University Shanghai Cancer Center, is the first to demonstrate the efficacy and safety of dual-epitope HER2 ADC TQB2102 in the neoadjuvant treatment of breast cancer [1] - The results were published online in the prestigious Journal of Clinical Oncology, which has an impact factor of 43.4 [1] Group 2 - A Phase III registration clinical study for TQB2102 is currently underway [1]

Core Viewpoint - China Biologic Products (01177) saw a stock increase of over 4%, currently trading at 7.16 HKD with a transaction volume of 174 million HKD, following the publication of positive Phase II clinical trial results for TQB2102 in the treatment of HER2-positive breast cancer [1] Group 1 - The Phase II clinical study results for TQB2102, a targeted antibody-drug conjugate (ADC) developed by China Biologic's subsidiary, Zhengda Tianqing, were published online in the Journal of Clinical Oncology [1] - TQB2102 targets two non-overlapping epitopes, ECD2 and ECD4, of HER2, demonstrating good efficacy and safety in the neoadjuvant treatment phase for breast cancer [1] - The study was led by Professor Shao Zhimin's team from Fudan University Shanghai Cancer Center, marking the first evidence of dual-epitope HER2 ADC TQB2102's effectiveness in this treatment stage [1] Group 2 - A Phase III registration clinical study for TQB2102 is currently underway, indicating ongoing development and potential future market introduction [1]

Key Takeaways from China Biopharma Trip Industry Overview - The trip focused on the Chinese biopharmaceutical industry, highlighting the rapid development of local biotech companies and their competitive landscape in drug discovery and clinical R&D [3][5][9]. Core Insights 1. **Rapid Development of Biotech Companies**: Local Chinese biotech firms have shown a remarkable pace of development, with examples like Pyrotech achieving clinical proof-of-concept in 4 years and Hengrui progressing from preclinical studies to IND acceptance in 6 months [3]. 2. **Factors Driving Speed**: Key factors contributing to this accelerated development include streamlined decision-making, a concentrated ecosystem of contract research organizations (CROs), strong fundamental research, and experienced clinical investigators [3]. 3. **Licensing and Partnerships**: Chinese biotech companies generally prefer licensing out their products, but more mature firms are increasingly seeking co-development and co-commercialization agreements, as seen with Innovent's partnership with Takeda [4]. 4. **Pipeline Diversity**: Companies visited exhibited broad pipelines across multiple disease areas, with a notable focus on antibody-drug conjugates (ADCs) and a competitive landscape characterized by intense pressure [5]. 5. **Obesity Market Developments**: Eccogene is optimistic about its obesity drug ECC5004, while Innovent noted rapid uptake of mazdutide, indicating strong competition in the obesity segment [7]. 6. **Vaccine Market Challenges**: Zhifei highlighted ongoing challenges in the vaccine market due to vaccine hesitancy and pricing pressures, complicating commercialization efforts [8]. Competitive Landscape 1. **ADC Focus**: Nearly half of the companies visited are engaged in ADC research, particularly in oncology, indicating China's emergence as an ADC hub [5]. 2. **Emerging Therapies**: Companies are exploring bispecific/trispecific antibodies and new-generation cell therapies, with a focus on innovative approaches to cancer treatment [5][31]. 3. **Market Dynamics**: The Chinese pharmaceutical market is valued at $160-180 billion, with the innovative market growing at 20-30% annually, expected to reach $50-60 billion in five years [23]. Company-Specific Highlights 1. **3SBio and Pfizer**: 3SBio expressed optimism regarding its PD-1xVEGF bispecific antibody program, with plans for multiple trials to establish the compound as a backbone therapy [9]. 2. **Kelun Biotech**: Kelun is advancing its TROP2 targeting ADC, sac-TMT, with expectations of significant peak sales based on recent clinical data [10]. 3. **Hengrui's Lp(a) Program**: Hengrui is encouraged by Phase 2 data for its Lp(a) targeted oral small molecule drug, which could transform cardiovascular disease treatment [10]. 4. **Zhifei's Gardasil Challenges**: Zhifei reported difficulties in the vaccine market, particularly with Gardasil, due to pricing pressures and vaccine hesitancy [10]. Additional Observations - **Regulatory Environment**: Sanofi noted that early-stage R&D in China is 50% cheaper and 60% faster than in the US, with plans to invest more in local partnerships [23]. - **Pricing Dynamics**: The conversation with obesity experts revealed insights into pricing dynamics and the competitive landscape for obesity treatments [7]. Conclusion The trip underscored the dynamic nature of the Chinese biopharma industry, characterized by rapid innovation, strategic partnerships, and a competitive landscape that poses both opportunities and challenges for local and multinational companies [3][5][23].

Core Viewpoint - China National Pharmaceutical Group's subsidiary, Lixin Pharmaceutical Technology, has received clinical trial approval from the NMPA for its innovative drug LM-350, a CDH17-targeted antibody-drug conjugate (ADC) [1][2] Group 1: Product Development - LM-350 is developed based on Lixin's next-generation LM-ADC™ platform and selectively binds to CDH17, demonstrating strong internalization capabilities [1] - The drug utilizes an IgG1 wild-type configuration and exhibits antibody-dependent cellular cytotoxicity (ADCC) activity [1] - Preclinical studies show significant anti-tumor activity of LM-350 in various xenograft models, particularly in colorectal cancer models resistant to MMAE or irinotecan [1] Group 2: Market Potential - CDH17 is highly expressed in various cancers, including approximately 99% in colorectal cancer, 86% in gastric adenocarcinoma, 79% in esophageal adenocarcinoma, and 50% in pancreatic ductal adenocarcinoma [1] - Gastrointestinal cancers, including colorectal, gastric, pancreatic, and esophageal cancers, represent one of the highest incidence and mortality rates globally, with over 4 million new cases reported in 2022, indicating a significant unmet clinical need [1] Group 3: Regulatory Progress - LM-350 has previously received IND approval from the FDA, with the first patient enrollment in Australia expected by September 2025 [2] - The approval of the clinical trial application in China will accelerate the clinical research process, aiming to provide new treatment options for patients sooner [2]

格隆汇11月18日丨中国生物制药(01177.HK)宣布，集团全资附属公司礼新医药科技(上海)有限公司("礼 新医药")自主研发的国家1类创新药LM-350"CDH17抗体偶联药物(ADC)"已获得中国国家药品监督管理 局(NMPA)的临床试验批准。 根据披露，LM-350是基于礼新医药新一代LM-ADC?平台开发的一款靶向CDH17的ADC，能够高度选择 性地结合CDH17，具有很强的内化能力。LM-350采用IgG1野生型构型，同时具备抗体依赖细胞介导的 细胞毒性作用(ADCC)活性。临床前研究显示，LM-350在多个异种移植模型中表现出显著的抗肿瘤活 性，尤其在对MMAE耐药或伊立替康耐药的结直肠癌移植瘤模型中效果突出。 ...

Core Viewpoint - China National Pharmaceutical Group's subsidiary, Lixin Pharmaceutical Technology (Shanghai) Co., Ltd., has received clinical trial approval from the National Medical Products Administration (NMPA) for its self-developed innovative drug LM-350, a CDH17 antibody-drug conjugate (ADC) [1][2] Group 1: Product Development - LM-350 is developed based on Lixin's next-generation LM-ADC platform, specifically targeting CDH17 with high selectivity and strong internalization capability [1] - The drug utilizes an IgG1 wild-type configuration and exhibits antibody-dependent cellular cytotoxicity (ADCC) activity [1] - Preclinical studies have shown significant anti-tumor activity of LM-350 in various xenograft models, particularly in colorectal cancer models resistant to MMAE or irinotecan [1] Group 2: Market Potential - CDH17 is highly expressed in various cancers, including approximately 99% in colorectal cancer, 86% in gastric adenocarcinoma, 79% in esophageal adenocarcinoma, and 50% in pancreatic ductal adenocarcinoma [1] - Gastrointestinal cancers, including colorectal, gastric, pancreatic, and esophageal cancers, represent one of the highest incidence and mortality rates globally, with over 4 million new patients reported in 2022, indicating a significant unmet clinical need [1] Group 3: Regulatory Progress - LM-350 has previously received an Investigational New Drug (IND) approval from the U.S. Food and Drug Administration (FDA) and is set to complete its first patient enrollment in Australia by September 2025 [2] - With the approval of the clinical trial application in China, Lixin Pharmaceutical aims to accelerate clinical research in China to provide new treatment options for patients as soon as possible [2]